Anyfusion cylinder pump and cylinder cartridge selected as 2023 Outstanding R&D Innovation Products by the Ministry of SMEs and Startups.

The Anyfusion cylinder pump and cylinder cartridge were selected as outstanding R&D innovative products by the Ministry of SMEs and Startups.

The Anyfusion cylinder pump should have been selected in June by passing the 8th stage of the 9-step screening by June 2023, but the Procurement Research Institute's own interpretation that the Anyfusion cylinder pump does not perform innovative functions as a pump alone and that the cylinder cartridge is innovative only when it is combined with the pump is not correct. The company's argument that the pump and cartridge are innovative and should be designated separately is similar to Samsung's cell phones, which perform and function as a combination of memory and OS, just as memory and OS are recognized as innovative products, The KITIE agreed with the company's argument that the pump and the cartridge were each innovative and should be designated as innovative products separately, and negotiated with the procurement research institute from June to November, but it was not accepted, so it was finally selected as a combined product.

The decision to classify the product as a combined product was made because we were concerned that the value of each product would not be recognized if it was classified as a combined innovation in the European and American public procurement markets, which have a large global market. The company's request to call the procurement research institute directly and explain the actual product was rejected and not allowed to visit. It is unfortunate that government-related researchers who only examined fast follow technology and only examined fast follow technology products in Korea, where there are no cases of leading global innovation by developing the original technology, memory and OS, as well as innovation in the telecommunications market, developed the original technology, First Mover. I hope it is not the case that we do not take the opportunity to lead market innovation by our original technology in the 20 trillion won drug infusion pump market and the global market for drug mixtures (anti-cancer (injection) drugs).

On the same level, Anyfusion cylinder pump was not designated as an innovative medical device by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare's Innovative Medical Device Company Selection System because it was not even examined for documents, but at the FDA, with only documents, the examiner identified it as an innovative medical device and directly introduced and supported STeP, and the examination was selected for intensive examination for 60 days, including Saturdays and Sundays, by the deputy director of the FDA.

We are responsible for not recognizing the innovativeness of our original technologies in the global market. Researchers at the Public Procurement Service, like those at the Ministry of Food and Drug Safety and the Ministry of Health and Welfare, are stuck in a backward-looking, frog-in-a-well mentality because there are no success stories with Korean original technologies.

This result means that if we apply and are selected for the first innovative medical device designation system in Korea in the European and American public procurement markets, we will be able to achieve rapid certification and marketization, but we will face a considerable disadvantage when submitting reference documents because we are defined as a combination of innovative products rather than individual innovative products in Korea, which has the original technology. It is unfortunate that the world-class innovative products that we have developed are not properly evaluated due to stereotypes, capabilities, and limitations of the level. I can discuss this later, but I am very sorry for our limitations. It is so difficult to start a venture in Korea.

If it is selected as an excellent R&D innovative product and receives a certificate around January 15, it is expected to help revitalize the domestic market by being included in the preferential purchase system for public hospitals. Although we have been selected for the scheme, we need the cooperation of the actual medical staff and the company's sales.

We would like to express our gratitude to the members of KIJUNG for their best efforts for the selection.